Dr. Craig S. Moore
Canada Research Chair in Neuroscience and Brain Repair
Targeting molecules in the human body to repair damage by chronic neurodegenerative diseases.
This research will identify new treatments for chronic neurodegenerative diseases such as multiple sclerosis.
Triggering the central nervous system to repair itself
Dr. Moore's research program aims to identify and test novel drug targets for treating chronic neurodegenerative diseases. In Canada and much of the developing world, the increasing incidence of brain-related diseases emphasizes the need to further research and develop more effective drugs that can benefit the quality of life in individuals suffering from such illnesses. A particular focus of
Dr. Moore's laboratory is to understand how inflammation in the brain leads to injury and repair. In the field of multiple sclerosis (MS) research, Dr. Moore has identified several different molecules in the human body that could be targeted to promote repair in the damaged brain and are relevant in several neurological conditions, such as MS, stroke, brain cancers, Alzheimer’s, amyotrophic lateral sclerosis (ALS), and traumatic brain injury. Together with his collaborators in industry and academia, he is raising awareness that in a supportive environment, the human brain has evolved the ability to endure injury and stimulate repair.
Dr. Moore’s research encompasses both in vitro (cell culture) and in vivo (live animal) studies. In vitro studies include the use of primary rodent and human neural cells (astrocytes, microglia, oligodendrocytes, neurons), which are designed to investigate the individual cellular mechanisms related to inflammation, injury and survival. Primary immune cells (T & B lymphocytes, myeloid cell populations) are also cultured in vitro to observe how immune cell-neural cell interactions contribute to neural cell-specific injury. In vitro studies also allow the introduction or removal of genes and microRNAs within individual immune and neural cell types. Through genetic manipulation via cellular transfection, it is possible to alter the cell phenotype and function and relate it to in situ observations. Using transgenic and pharmacological approaches, in vivo experiments complement in vitro findings and help validate novel drug targets related to decreasing inflammation and promoting repair in the CNS.